TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
BOSTON, March 22, 2017 -- Block & Leviton LLP (www.blockesq.com), a Boston-based securities litigation firm representing investors nationwide, reminds investors of PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKTS:PXRB) of the March 27, 2017 lead plaintiff deadline.
If you purchased PixarBio securities in either the Company’s private placement, or on the open market between October 31, 2016 and January 20, 2017, you are encouraged to contact attorney Bradley Vettraino at (617) 398-5600, by email at [email protected], or by visiting www.blockesq.com/pixarbio.
On January 3, 2017, PixarBio's CEO announced a purported attempt by the Company to acquire InVivo Therapeutics Holdings Corp. ("InVivo") in a $100 million takeover bid. InVivo refuted PixarBio’s purported offer as "not credible." On January 23, 2017, the SEC announced that it had halted trading in the securities of PixarBio, citing concerns about possible "manipulative or deceptive activities" in the market for the Company's stock.
PixarBio’s stock plunged more than 35% during the month of January, causing tens of millions in losses to investors.
The lawsuit subsequently filed by Block & Leviton against PixarBio and its CEO, in the United States District Court for Massachusetts alleges that Defendants failed to disclose and/or made false and/or misleading statements regarding: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; (3) the company’s current and prospective development efforts, and (4) that, as a result, the Company’s business, operations, and prospects, were false and misleading.
As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.
Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.
This notice may constitute attorney advertising.
CONTACT: Block & Leviton LLP Bradley J. Vettraino 155 Federal Street, Suite 400 Boston, MA 02110 (617) 398-5600 [email protected]
